Please use this identifier to cite or link to this item:
Title: Penumbral selection of patients for trials of acute stroke therapy.
Austin Authors: Donnan, Geoffrey A ;Baron, Jean-Claude;Ma, Henry K;Davis, Stephen M
Affiliation: National Stroke Research Institute, Austin Health, University of Melbourne, Australia
Issue Date: 1-Mar-2009
Publication information: The Lancet. Neurology; 8(3): 261-9
Abstract: After ischaemic stroke onset, potentially viable (ie, penumbral) tissue might be salvageble for as long as 48 h. By increasing the therapeutic time window for treatment of stroke with intravenous alteplase from 3-4.5 h to 9 h, many more patients could be treated. Use of a combination of diffusion-weighted and perfusion-weighted MRI or perfusion CT might improve selection of patients with penumbral tissue. Several phase II trials of alteplase lend strong biological support to the use of this strategy for up to 6 h after stroke. However, the negative results of the phase III Desmoteplase In Acute ischaemic Stroke trial (DIAS-2) with desmoteplase given up to 9 h after stroke suggest that some refinements are needed. For trials of neuroprotection, the concept of freezing the penumbra (ie, preventing further deterioration of the vulnerable tissue) might be a more realistic expectation. Recent advances in penumbral imaging technology should enable a phase III alteplase trial to be done beyond 4.5 h by use of techniques to select patients with penumbral tissue.
Gov't Doc #: 19233036
DOI: 10.1016/S1474-4422(09)70041-9
Type: Journal Article
Subjects: Clinical Trials as Topic
Fibrinolytic Agents.therapeutic use
Magnetic Resonance Imaging
Patient Selection
Plasminogen Activators.therapeutic use
Stroke.drug therapy.pathology
Time Factors
Tissue Plasminogen Activator.therapeutic use
Tomography, X-Ray Computed
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 9, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.